Clinical Trial Update: A Study to Determine the Effect of CT3001 in Patients with Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of CT3001 in adults with advanced solid tumors is currently recruiting, including colorectal cancer and pancreatic ductal adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• CT3001

Snippet

Sponsor: Crossignal Therapeutics, Inc. | Conditions: Solid Tumor, Adult, Colorectal Cancer | Phase 1, Phase 2 | Status: RECRUITING